Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
30.79
-0.26 (-0.84%)
Mar 9, 2026, 2:25 PM EDT - Market open
Teva Pharmaceutical Revenue
In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth. Teva Pharmaceutical had revenue of $4.71B in the quarter ending December 31, 2025, with 11.40% growth.
Revenue (ttm)
$17.26B
Revenue Growth
+4.32%
P/S Ratio
2.08
Revenue / Employee
$508,336
Employees
33,950
Market Cap
35.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.48B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Zoetis | 9.47B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Neurocrine Biosciences | 2.86B |
TEVA News
- 2 days ago - The 3 Best Stocks to Invest $1,000 in Right Now - The Motley Fool
- 4 days ago - Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's - Nasdaq
- 4 days ago - Forget Teva: This Dividend Top Dog Is the Real Value Buy Today - The Motley Fool
- 5 days ago - 3 Generic Drug Stocks to Watch Despite Industry Headwinds - Nasdaq
- 5 days ago - Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News - GuruFocus
- 5 days ago - Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding - The Motley Fool
- 5 days ago - Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug - Nasdaq
- 5 days ago - Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development - GuruFocus